Merck (MRK) Asset Writedowns and Impairment (2010 - 2023)

Merck has disclosed Asset Writedowns and Impairment across 14 years of filings, most recently posting $779.0 million for Q4 2023.

• In Q4 2023, Asset Writedowns and Impairment fell 7.15% year-over-year to $779.0 million; the TTM figure through Dec 2023 stood at $2.8 billion (up 38.41% YoY), while the FY2025 annual figure was $55.0 million, up 41.03% from the prior year.
• Asset Writedowns and Impairment slipped to $779.0 million in Q4 2023, from $839.0 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for MRK reached as high as $1.7 billion in Q4 2020 and fell as low as $15.0 million in Q3 2020.
• The 5-year median for Asset Writedowns and Impairment is $302.0 million (2021), against an average of $505.9 million.
• The widest YoY moves for Asset Writedowns and Impairment: up 856.25% in 2020, down 97.55% in 2020.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $176.0 million in 2019, then surged by 856.25% to $1.7 billion in 2020, then slumped by 82.06% to $302.0 million in 2021, then soared by 177.81% to $839.0 million in 2022, then decreased by 7.15% to $779.0 million in 2023.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $779.0 million, $839.0 million, and $887.0 million for Q4 2023, Q4 2022, and Q3 2022 respectively.